Effect of starting dose of regorafenib on overall survival of patients with metastatic colorectal cancer: a systematic review and meta-analysis

摘要: Aim. To conduct a systematic review and meta-analysis of studies on the effect starting dose regorafenib overall survival (OS) patients with chemorefractory metastatic colorectal cancer. Materials methods. We searched for research data in PubMed. The analysis included all publications till 08.20.2019 which compared OS depending (160 mg or less) 1st course therapy. Meta-analysis was conducted using Review Manager Ver. 5.3. Results. Two demonstrated decreased at less than 160 (A. Adenis et al., 2016: risk ratio - RR 1.26, 95% confidence interval CI 1.01-1.56; A. Aljubran 2019: 2.25, 0.93-5.43). showed an improvement (T. Bekaii-Saab 2018: 0.72, 0.47-1,11; J. Gotfrit 2017: 0.46, 0.17-1.22). In two other studies, there no (K. Yamaguchi 0.95, 0.82-1.1; G. Argiles 0,86, 0.65-1.13). did not reveal drug OS: 0.97, 0.78-1.21; p=0.79; I2=64. Conclusions. Reducing does decrease can be recommended routine clinical practice.